POMC and Anxiety: This randomized, double-blind, placebo-controlled clinical trial demonstrated that an 8-week supplementation with PS128 and HT-PS23 produced significant group × time interactions for specific subscales of mental health assessments, including JSS general health, STAI state anxiety absent, ISI early awakening, and ISI total, while concurrently reducing ACTH and norepinephrine concentrations.